Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Reimann

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Seminars in Oncology|November 13, 2003
A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancerMelody A Cobleigh, Virginia K Langmuir, George W Sledge, et al.
Ophthalmology|May 12, 2005
Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degenerationPhilip J Rosenfeld, Steven D Schwartz, Mark S Blumenkranz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2005
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancerKathy D Miller, Linnea I Chap, Frankie A Holmes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2011
Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancerAdrian M Jubb, Kathy D Miller, Hope S Rugo, et al.
The Journal of Clinical Endocrinology and Metabolism|October 5, 2002
The pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient adultsD M Cook, B M K Biller, M L Vance, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Seminars in Oncology|November 13, 2003
A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancerMelody A Cobleigh, Virginia K Langmuir, George W Sledge, et al.
Ophthalmology|May 12, 2005
Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degenerationPhilip J Rosenfeld, Steven D Schwartz, Mark S Blumenkranz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2005
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancerKathy D Miller, Linnea I Chap, Frankie A Holmes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2011
Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancerAdrian M Jubb, Kathy D Miller, Hope S Rugo, et al.
The Journal of Clinical Endocrinology and Metabolism|October 5, 2002
The pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient adultsD M Cook, B M K Biller, M L Vance, et al.
Pageof 3